Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights
30 mars 2023 07h30 HE
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical...
Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference
07 mars 2023 08h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
31 janv. 2023 06h00 HE
|
Reviva Pharmaceuticals
Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces Letter to Shareholders
04 janv. 2023 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
15 déc. 2022 06h00 HE
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated...
Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208
21 nov. 2022 06h00 HE
|
Reviva Pharmaceuticals
- RP1208 is in preclinical development for the potential treatment of depression and obesity – - Composition of matter patents for RP1208 have been granted in key markets around the world including...
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
14 nov. 2022 16h05 HE
|
Reviva Pharmaceuticals
- Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial - - Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 - - $23.2...
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
31 oct. 2022 08h00 HE
|
Reviva Pharmaceuticals
- Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 - - Enrollment on pace, with over 30% enrolled in the United States - - Topline data...
Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference
26 sept. 2022 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 08h02 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...